Jason A. Keyes, Equillium CEO, Inc. (Nasdaq :), a biotechnology company with a market capitalization of $ 24.4 million and a strong position of liquidity, as indicated by a 3,04x current ratio, recently sold 10,000 Common stock stocks. The shares were sold at a weighted average price of $ 0.65, which amounts to a total transaction value of $ 6,500. This transaction occurred with stock trade at 79% below 52-week maximum of $ 3.25, due to significant prices instability. After this sale, Keyes owns 37,720 shares indirectly through Keyes Trust -Ai 88.913 shares directly. Sales was made according to a pre-established trading plan of 10b5-1, which Keyes was adopted on March 27, 2024. According to Investment Analysis, Equillium currently shows signs of fast -in -law of cash, with several additional key measuring data and insights available to subscribers.
In other recent news, Equillium Inc . He experienced a number of significant events. Jones Traring reduced the stock Equillium -as “buy” on “Hold” after the decision -a decision Pharmaceutical (Tywul 🙂 Do not continue to acquire itolizumab, leaving an equillium with full commercial rights to the drug. This lack of expected payments has led to the financial challenges for Equillium, which has potentially influenced the end of phase 3 equator experiment in acute vaccination compared to the host disease (AGVHD).
In addition, Equillium considers the acceleration of the end of the Equatorial Study until the beginning of 2025 and expects to publish in the same time frame on the top line from the Ulcerative Colitis Study in phase 2. The company has stopped further development of other pipeline projects, EQ101 and EQ302, to focused on itolizumab.
Equillium recently reported that $ 33.3 million was estimated in cash, monetary equivalents and short -term investments. AND Independent (Lon 🙂 Data Supervision Committee (IDMC) allowed the continuation of the testing of itolizumab without changes based on security and efficiency assessment. These are all recent movements in the company’s business.
This article was generated with the support of AI and was examined by the editor. See our T&C for more information.
